Tag: Longevity
18 predictions tagged with "Longevity".
The First Efficacy Results From The TAME (Targeting Aging With Metformin) Trial Are Expected To Be Published Between 2027 And 2028, Providing The First Strong Signal On Whether Metformin Delays The First Onset Of Age-related Diseases In Non-diabetic Adults Aged 65-79.2027 · Longevity
Drugs That Regulate The Circadian Rhythm (Biological Clock) Are Expected To Be Developed.2027 · Longevity
Wearable Devices For Sleep Optimization Are Expected To Become Widespread.2027 · Longevity
Anti-aging Molecules (Senolytics) Are Expected To Show Promising Results In Clinical Trials.2027 · Longevity
Sleep Tracking Devices (Such As The Oura Ring) Are Expected To Gain Independent Clinical Validation And Regulatory Clarity On Sleep-stage Accuracy By 2028, With Device Data From Millions Of Users Increasingly Integrated Into Primary Care Monitoring.2028 · Longevity
Biological Age Measurement (Epigenetic Clock) Is Expected To Enter Routine Health Screening.2028 · Longevity
Neuromodulation Devices That Improve Sleep Quality Are Expected To Become Commercial.2028 · Longevity
Drugs That Slow The Aging Process Are Expected To Succeed In Clinical Trials.2028 · Longevity
By The End Of 2028, Biological Age Measurement And AI-driven Target Discovery Will Become A Standard Component Of Preclinical Longevity Programs, Used İn At Least 50% Of Such Programs.2028 · Longevity
Biological Age Measurement Is Expected To Start Being Used By Health Insurers.2029 · Longevity
Neuromodulation Devices For Sleep Optimization Are Expected To Become Standard.2029 · Longevity
Anti-aging Drugs Are Expected To Enter Clinical Use.2029 · Longevity
The First Senolytic Drug (Which Clears Aged 'zombie Cells') Is Expected To Gain Regulatory Approval For An Age-related Indication Or Reach Phase 3 By 2030, As More Than 30 Senolytic Clinical Trials Mature Into Results.2030 · Longevity
Biological Age Measurement Is Expected To Become Mandatory For Health Insurers.2030 · Longevity
Neuromodulation Devices For Sleep Optimization Are Expected To Become Widespread.2030 · Longevity
Anti-aging Drugs Are Expected To Noticeably Extend Lifespan.2030 · Longevity
Interim Results From The First Large Human Trials Testing Whether GLP-1 Drugs (Such As Semaglutide) Slow Aging Are Expected By 2031, Clarifying Whether These Drugs, Which Extended Mouse Lifespan By About 12 Percent, Affect Biological Aging Markers In Humans.2031 · Longevity
At Least One AI-discovered Drug Candidate Aimed At Extending Lifespan Is Expected To Enter Human Clinical Trials By 2034, With Tools Such As AlphaFold Compressing Drug Discovery Timelines From Years To Months.2034 · Longevity
